Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma

A retrospective analysis

Ha Young Lee, Sang Joon Shin, Hyo Song Kim, Soo Jung Hong, Jung Woo Han, Seung Taek Lim, Jae Kyung Roh, SunYoung Rha

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Purpose The combination of gemcitabine and docetaxel (GD) is used to effectively treat patients with soft tissue sarcoma (STS). It is widely considered that the conventional doses used are too high for long term use and many patients must discontinue GD treatment due to its toxicity. Therefore, to determine the appropriate dose meeting acceptable efficacy results, while minimizing toxic side effects, we treated patients with a weekly infusion of GD (weekly GD). Materials and Methods A total of 22 patients presenting a variety of STSs were treated at Yonsei Cancer Center. All patients had metastatic or recurrent cancer and had previously received doxorubicin and ifosfamide combination chemotherapy. In all cases, gemcitabine (1,000 mg/m 2) and docetaxel (35 mg/m 2) were administered intravenously on days 1 and 8 of a 21-day cycle. We retrospectively reviewed the medical records of these patients. Results The response rate was 4.5%, with one patient diagnosed with leiomyosarcoma having a partial response, and the disease control rate was 40.9%. The median progression-free survival (PFS) duration was 2.7 months and the PFS was correlated with the treatment response to a weekly GD. The median overall survival (OS) duration was 7.8 months and the OS was correlated with histology. There was no significant difference in OS between patients who received weekly GD as a 2nd line chemotherapy and those who received 3rd line or more. Treatment was generally well tolerated. Conclusion Weekly GD was well tolerated and showed moderate efficacy, indicating that this could be a reasonable option as a salvage treatment for metastatic STS.

Original languageEnglish
Pages (from-to)43-49
Number of pages7
JournalCancer Research and Treatment
Volume44
Issue number1
DOIs
Publication statusPublished - 2012 Mar 1

Fingerprint

docetaxel
gemcitabine
Sarcoma
Disease-Free Survival
Survival
Salvage Therapy
Ifosfamide
Leiomyosarcoma
Poisons
Combination Drug Therapy
Doxorubicin
Medical Records

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Lee, Ha Young ; Shin, Sang Joon ; Kim, Hyo Song ; Hong, Soo Jung ; Han, Jung Woo ; Lim, Seung Taek ; Roh, Jae Kyung ; Rha, SunYoung. / Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma : A retrospective analysis. In: Cancer Research and Treatment. 2012 ; Vol. 44, No. 1. pp. 43-49.
@article{397c76c31f854cf9a1f1f0ffaee380b9,
title = "Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma: A retrospective analysis",
abstract = "Purpose The combination of gemcitabine and docetaxel (GD) is used to effectively treat patients with soft tissue sarcoma (STS). It is widely considered that the conventional doses used are too high for long term use and many patients must discontinue GD treatment due to its toxicity. Therefore, to determine the appropriate dose meeting acceptable efficacy results, while minimizing toxic side effects, we treated patients with a weekly infusion of GD (weekly GD). Materials and Methods A total of 22 patients presenting a variety of STSs were treated at Yonsei Cancer Center. All patients had metastatic or recurrent cancer and had previously received doxorubicin and ifosfamide combination chemotherapy. In all cases, gemcitabine (1,000 mg/m 2) and docetaxel (35 mg/m 2) were administered intravenously on days 1 and 8 of a 21-day cycle. We retrospectively reviewed the medical records of these patients. Results The response rate was 4.5{\%}, with one patient diagnosed with leiomyosarcoma having a partial response, and the disease control rate was 40.9{\%}. The median progression-free survival (PFS) duration was 2.7 months and the PFS was correlated with the treatment response to a weekly GD. The median overall survival (OS) duration was 7.8 months and the OS was correlated with histology. There was no significant difference in OS between patients who received weekly GD as a 2nd line chemotherapy and those who received 3rd line or more. Treatment was generally well tolerated. Conclusion Weekly GD was well tolerated and showed moderate efficacy, indicating that this could be a reasonable option as a salvage treatment for metastatic STS.",
author = "Lee, {Ha Young} and Shin, {Sang Joon} and Kim, {Hyo Song} and Hong, {Soo Jung} and Han, {Jung Woo} and Lim, {Seung Taek} and Roh, {Jae Kyung} and SunYoung Rha",
year = "2012",
month = "3",
day = "1",
doi = "10.4143/crt.2012.44.1.43",
language = "English",
volume = "44",
pages = "43--49",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Cancer Association",
number = "1",

}

Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma : A retrospective analysis. / Lee, Ha Young; Shin, Sang Joon; Kim, Hyo Song; Hong, Soo Jung; Han, Jung Woo; Lim, Seung Taek; Roh, Jae Kyung; Rha, SunYoung.

In: Cancer Research and Treatment, Vol. 44, No. 1, 01.03.2012, p. 43-49.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma

T2 - A retrospective analysis

AU - Lee, Ha Young

AU - Shin, Sang Joon

AU - Kim, Hyo Song

AU - Hong, Soo Jung

AU - Han, Jung Woo

AU - Lim, Seung Taek

AU - Roh, Jae Kyung

AU - Rha, SunYoung

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Purpose The combination of gemcitabine and docetaxel (GD) is used to effectively treat patients with soft tissue sarcoma (STS). It is widely considered that the conventional doses used are too high for long term use and many patients must discontinue GD treatment due to its toxicity. Therefore, to determine the appropriate dose meeting acceptable efficacy results, while minimizing toxic side effects, we treated patients with a weekly infusion of GD (weekly GD). Materials and Methods A total of 22 patients presenting a variety of STSs were treated at Yonsei Cancer Center. All patients had metastatic or recurrent cancer and had previously received doxorubicin and ifosfamide combination chemotherapy. In all cases, gemcitabine (1,000 mg/m 2) and docetaxel (35 mg/m 2) were administered intravenously on days 1 and 8 of a 21-day cycle. We retrospectively reviewed the medical records of these patients. Results The response rate was 4.5%, with one patient diagnosed with leiomyosarcoma having a partial response, and the disease control rate was 40.9%. The median progression-free survival (PFS) duration was 2.7 months and the PFS was correlated with the treatment response to a weekly GD. The median overall survival (OS) duration was 7.8 months and the OS was correlated with histology. There was no significant difference in OS between patients who received weekly GD as a 2nd line chemotherapy and those who received 3rd line or more. Treatment was generally well tolerated. Conclusion Weekly GD was well tolerated and showed moderate efficacy, indicating that this could be a reasonable option as a salvage treatment for metastatic STS.

AB - Purpose The combination of gemcitabine and docetaxel (GD) is used to effectively treat patients with soft tissue sarcoma (STS). It is widely considered that the conventional doses used are too high for long term use and many patients must discontinue GD treatment due to its toxicity. Therefore, to determine the appropriate dose meeting acceptable efficacy results, while minimizing toxic side effects, we treated patients with a weekly infusion of GD (weekly GD). Materials and Methods A total of 22 patients presenting a variety of STSs were treated at Yonsei Cancer Center. All patients had metastatic or recurrent cancer and had previously received doxorubicin and ifosfamide combination chemotherapy. In all cases, gemcitabine (1,000 mg/m 2) and docetaxel (35 mg/m 2) were administered intravenously on days 1 and 8 of a 21-day cycle. We retrospectively reviewed the medical records of these patients. Results The response rate was 4.5%, with one patient diagnosed with leiomyosarcoma having a partial response, and the disease control rate was 40.9%. The median progression-free survival (PFS) duration was 2.7 months and the PFS was correlated with the treatment response to a weekly GD. The median overall survival (OS) duration was 7.8 months and the OS was correlated with histology. There was no significant difference in OS between patients who received weekly GD as a 2nd line chemotherapy and those who received 3rd line or more. Treatment was generally well tolerated. Conclusion Weekly GD was well tolerated and showed moderate efficacy, indicating that this could be a reasonable option as a salvage treatment for metastatic STS.

UR - http://www.scopus.com/inward/record.url?scp=84865195672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865195672&partnerID=8YFLogxK

U2 - 10.4143/crt.2012.44.1.43

DO - 10.4143/crt.2012.44.1.43

M3 - Article

VL - 44

SP - 43

EP - 49

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 1

ER -